featured
Acalabrutinib Plus Venetoclax and Rituximab for Treatment-Naïve Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
Blood Adv 2024 Sep 10;9(17)4539-4548, ML Wang, T Robak, KJ Maddocks, TJ Phillips, SD Smith, D Gallinson, R Calvo, CC Wun, V Munugalavadla, W JurczakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.